GoldenGolden
Biofire Diagnostics

Biofire Diagnostics

A biotechnology company that detects pathogens and mutations to diagnose syndromic infectious disease

All edits

Edits on 6 Oct, 2020
Golden AI"Funding autocalculation"
Golden AI edited on 6 Oct, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Latest funding round date
September 19, 2012
Edits on 19 Aug, 2020
Lax Mariappan
Lax Mariappan edited on 19 Aug, 2020
Edits made to:
Infobox (+3 properties)
Infobox
CEO
Kirk Ririe
Founder
Edits on 31 Jul, 2020
Aleksander Holm
Aleksander Holm edited on 31 Jul, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 17 Jul, 2020
Golden AI"Funding autocalculation"
Golden AI edited on 17 Jul, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Total funding amount (USD)
25,000,000
Edits on 2 Apr, 2020
Arthur Smalley
Arthur Smalley edited on 2 Apr, 2020
Edits made to:
Infobox (+1/-1 properties)
Infobox
Parent organization
Parent organization
Edits on 1 Apr, 2020
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 1 Apr, 2020
Edits made to:
Article (+11/-11 characters)
Article

Biofire Diagnostics, LLC is a biotechnology company that provides syndromic infectious disease diagnostic services. The Salt Lake City-based company was founded in 1990. In 2013, the company was acquired by France-based biotechnology and health diagnostics company BioMérieuxBioMérieux, becoming BioMérieux’s Global Center of Excellence for Molecular Diagnostics.

Arthur Smalley
Arthur Smalley edited on 1 Apr, 2020
Edits made to:
Article (+1983 characters)
Categories (+1 topics)
Article

Biofire Diagnostics, LLC is a biotechnology company that provides syndromic infectious disease diagnostic services. The Salt Lake City-based company was founded in 1990. In 2013, the company was acquired by France-based biotechnology and health diagnostics company BioMérieux, becoming BioMérieux’s Global Center of Excellence for Molecular Diagnostics.

Biofire produced the BioFire FilmArray System for comprehensive multiplex PCR testing. The FDA-cleared BioFire System panels test for viruses, bacteria, parasites, yeast, and antimicrobial resistance genes. The company has used its extensive patent portfolio to successfully market nearly 200 products to the clinical, research and military markets. For many pathogens, Biofire has both FDA-cleared and CE-IVD marked assays.

COVID-19

In collaboration with the Department of Defense, BioFire Defense has developed a fully-automated, sample-to-result assay for the specific detection of SARS-CoV-2, the causative agent of COVID-19. The test has been authorized by the FDA under Emergency Use Authorization (EUA). This assay is designed to run on both the BioFire FilmArray 2.0 and BioFire FilmArray Torch Systems, delivering results in about 45 minutes. After meeting initial DoD demand, commercial availability under EUA is anticipated in April of 2020.

...

In parallel, BioFire Diagnostics is developing new SARS-CoV-2-specific assays for addition to the BioFire FilmArray Respiratory 2 (RP2) Panel. This new panel is named the BioFire Respiratory 2.1 (RP2.1) Panel and is being developed for both the BioFire 2.0 and BioFire Torch Systems. In addition to the detection of SARS-CoV-2, the BioFire RP2.1 Panel will detect 21 additional respiratory pathogens to help clinicians quickly rule in and rule out other common causes of respiratory illness in about 45 minutes. Development of the BioFire RP2.1 Panel is occurring on an accelerated timeline, and submission to the FDA for EUA and 510(k) clearance is anticipated in Q3 of 2020.

Categories
Arthur Smalley
Arthur Smalley edited on 1 Apr, 2020
Edits made to:
Infobox (+11 properties)
Infobox
Legal name
BioFire Diagnostics, LLC.
Email address
support@biofiredx.com
Founded date
1991
Full address
515 Colorow Drive, Salt Lake City, Utah 84108, US
Parent organization
Edits on 18 Mar, 2020
Carla Faraguna
Carla Faraguna edited on 18 Mar, 2020
Edits made to:
Further reading (+2 rows) (+5 cells) (+234 characters)
Further reading

Title
Author
Link
Type
Date

Theranos patents at center of lawsuit over startup's COVID-19 tests - Business Insider

Aaron Holmes

Web

March 17, 2020

Edits on 12 Jun, 2019
Golden AI
Golden AI edited on 12 Jun, 2019
Edits made to:
Infobox (+1 properties)
Edits on 21 Jan, 2019
Golden AI"Changed markets to industries"
Golden AI edited on 21 Jan, 2019
Edits made to:
Infobox (+1/-1 properties)
Infobox
Edits on 10 Jan, 2019
Golden AI
Golden AI edited on 10 Jan, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 12 Dec, 2018
Golden AI"Import data"
Golden AI edited on 12 Dec, 2018
Edits made to:
Infobox (+3 properties)
People (+13 rows) (+26 cells) (+296 characters)
Categories (+1 topics)
People

Name
Role
Related Golden topics

Bianca Lui-Sargent

Employee

Charles McNall

Employee

Christopher Thurston

Employee

Emily Mearns

Employee

Eric Judd

Employee

Hope Vasic

Employee

Jay Walther

Employee

Joe McCullagh

Employee

Jordan Baczuk

Employee

Joshua James Wilson

Employee

Kirsen Sullivan

Employee

Nilesh P. Ingle, Ph.D.

Employee

Santosh Kolipaka

Employee

Infobox
Categories
Edits on 19 Jul, 2018
Golden AI"Update locations in infobox"
Golden AI edited on 19 Jul, 2018
Infobox
Edits on 29 Jun, 2018
Golden AI"Update infobox"
Golden AI edited on 29 Jun, 2018
Edits on 18 Jun, 2018
Golden AI"Updating description"
Golden AI edited on 18 Jun, 2018
Edits made to:
Description (+101/-21 characters)
Topic thumbnail

Biofire Diagnostics

Biotechnology company

A biotechnology company that detects pathogens and mutations to diagnose syndromic infectious disease

Edits on 29 May, 2018
Golden AI"Initial topic creation"
Golden AI created this topic on 29 May, 2018
Edits made to:
Description (+21 characters)
Categories (+1 topics)
Topic thumbnail

 Biofire Diagnostics

Biotechnology company

Categories
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.